Advertisement

Topics

Stratasys Releases Third Quarter 2017 Financial Results

07:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Company reports $155.9 million in revenue GAAP net loss of $10.2 million, or ($0.19) per diluted share, and non-GAAP net income of $4.1 million, or $0.08 per diluted share Company increasing full year 2017 earn...

Other Sources for this Article

Stratasys Investor Relations
Shane Glenn, 952-294-3416
Vice President - Investor Relations
shane.glenn@stratasys.com

NEXT ARTICLE

More From BioPortfolio on "Stratasys Releases Third Quarter 2017 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...